Who are UroGen Pharma Ltd.'s main suppliers?

UroGen Pharma Ltd. (URGN) key suppliers include: Agenus Inc., Aura Biosciences, Inc., Lite Strategy, Inc.. View the full supplier network at chainsifter.com/chain/URGN.

Who are UroGen Pharma Ltd.'s major customers?

UroGen Pharma Ltd. (URGN) key customers include: JELMYTO, ZUSDURI, ISOTOPIA-MOLECULAR-IMAGING-LTD, JPMorgan Chase & Co., JPMorgan Chase & Co. and 7 more. View the full customer network at chainsifter.com/chain/URGN.

What sector is UroGen Pharma Ltd. in?

UroGen Pharma Ltd. (URGN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

UroGen Pharma Ltd. Supplier List (URGN): 3 Verified Suppliers

3Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

UroGen Pharma Ltd. (URGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships

1Distinct source URLs

7High confidence

0.749Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

UroGen Pharma Ltd. Suppliers

Ticker	Name	Confidence	Evidence
AGEN	Agenus Inc.	72%	Reciprocal relationship from AGEN graph: — 2,057 Total $ 20,362 $ ( 17,325 ) $ 3,037 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense re…
AURA	Aura Biosciences, Inc.	72%	Reciprocal relationship from AURA graph: rts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to perform sales and marketing services, our…
LITS	Lite Strategy, Inc.	72%	Reciprocal relationship from LITS graph: compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive com…

UroGen Pharma Ltd. Customers

Ticker	Name	Confidence	Evidence
JELMYTO	JELMYTO	92%	All product sales of Jelmyto and Zusduri are recognized through the Company's arrangements with two customers as defined by ASC 606, both of which are third-party national specialty distributors.
ZUSDURI	ZUSDURI	92%	All product sales of Jelmyto and Zusduri are recognized through the Company's arrangements with two customers as defined by ASC 606, both of which are third-party national specialty distributors.
ISOTOPIA-MOLECULAR-IMAGING-LTD	ISOTOPIA-MOLECULAR-IMAGING-LTD	85%	political, economic and military conditions in Israel.* Our research and development facility is located in Ra’anana, Israel, and certain of our key vendors and suppliers, including Isotopia Molecula…
JPM-PD	JPMorgan Chase & Co.	72%	Reciprocal relationship from JPM-PD graph: Reciprocal relationship from URGN graph: Reciprocal relationship from JPM-PD graph: Reciprocal relationship from URGN graph: Reciprocal relationship from JP…
JPM-PD	JPMorgan Chase & Co.	72%	political, economic and military conditions in Israel.* Our research and development facility is located in Ra’anana, Israel, and certain of our key vendors and suppliers, including Isotopia Molecula…
ALLERGAN-PHARMACEUTICALS-LIMITED	ALLERGAN-PHARMACEUTICALS-LIMITED	62%	hion to support the initiation of clinical trials; • obtaining regulatory approval to commence clinical trials in any jurisdiction, including the submission and acceptance of INDs; • contracting with…
COMPANY-LLC	COMPANY-LLC	62%	ntifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. The cost of an asset acquisition is allocated to identifiable assets acquired…
GUGGENHEIM-SECURITIES-LLC	GUGGENHEIM-SECURITIES-LLC	62%	ntifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. The cost of an asset acquisition is allocated to identifiable assets acquired…
ICONOVIR-BIO-INC	ICONOVIR-BIO-INC	62%	eased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria. Serious adverse reac…
SILVERGATE-CAPITAL-CORP	SILVERGATE-CAPITAL-CORP	62%	political, economic and military conditions in Israel.* Our research and development facility is located in Ra’anana, Israel, and certain of our key vendors and suppliers, including Isotopia Molecula…
UROGEN-PHARMA-INC	UROGEN-PHARMA-INC	62%	ion 382 of the Code has occurred for UroGen Pharma, Inc. If we undergo or have undergone an ownership change, our ability to utilize NOLs and other tax attributes could be limited by Sections 382 and…
USA-LLC	USA-LLC	62%	ntifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. The cost of an asset acquisition is allocated to identifiable assets acquired…

UroGen Pharma Ltd. Debt Obligations

Instrument	Description	Confidence	Evidence
URGN-DEBT	Debt stack $188.7M	90%	Market cache reports total debt of $188.7M.
URGN-DEBT-13241	Warrants outstanding: 18641000	90%	xbrl warrant detail from xbrl 2024-12-31.
URGN-DEBT-13242	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

UroGen Pharma Ltd. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for UroGen Pharma Ltd..

UroGen Pharma Ltd. Ownership

Holder	Name	Confidence	Evidence
URGN-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 174 tracked holders.

UroGen Pharma Ltd. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CGON	CG Oncology, Inc.	100.00	2
AGEN	Agenus Inc.	100.00	1	['supplier']
JNJ	Johnson & Johnson	100.00	2
JPM-PD	JPMorgan Chase & Co.	100.00	1	['customer']
LITS	Lite Strategy, Inc.	100.00	1	['supplier']
CINF	Cincinnati Financial Corporation	50.00	2
CNTA	Centessa Pharmaceuticals plc	50.00	2
ACGL	Arch Capital Group Ltd.	50.00	2
YEXT	Yext, Inc.	50.00	2
CB	Chubb Limited	50.00	2
BMY	Bristol-Myers Squibb Company	50.00	2
BMYMP	Bristol-Myers Squibb Co	50.00	2
IDAI	T Stamp Inc.	50.00	2
HOLX	Hologic, Inc.	50.00	2
JPM	JPMorgan Chase & Co.	50.00	2
TVTX	Travere Therapeutics, Inc.	50.00	2
LNKB	LINKBANCORP, Inc.	50.00	2
PRU	Prudential Financial, Inc.	50.00	2
HLNE	Hamilton Lane Incorporated	50.00	2
INKT	MiNK Therapeutics, Inc.	50.00	2

UroGen Pharma Ltd. Supply Chain